NDC product
Brimonidine Tartrate and Timolol Maleate
NDC 0832-1425 · Upsher-Smith Laboratories, LLC
Key facts
| Product NDC | 0832-1425 |
|---|---|
| Proprietary name | Brimonidine Tartrate and Timolol Maleate |
| Nonproprietary name | Brimonidine Tartrate and Timolol Maleate |
| Substances | BRIMONIDINE TARTRATE, TIMOLOL MALEATE |
| Dosage form | SOLUTION/ DROPS |
| Route | OPHTHALMIC |
| Labeler | Upsher-Smith Laboratories, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA215598 |
| Pharmacologic classes | Adrenergic alpha-Agonists [MoA], Adrenergic beta-Antagonists [MoA], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Blocker [EPC] |
| Marketing start | Dec 15, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: